Advanced protein glycosylation in diabetes and aging - PubMed (original) (raw)
Review
Advanced protein glycosylation in diabetes and aging
M Brownlee. Annu Rev Med. 1995.
Abstract
Products of advanced protein glycosylation (advanced glycation end products, or AGEs) accumulate in tissues as a function of time and sugar concentration. AGEs induce permanent abnormalities in extracellular matrix component function, stimulate cytokine and reactive oxygen species production through AGE-specific receptors, and modify intracellular proteins. Pharmacologic inhibition of AGE formation in long-term diabetic animals prevents diabetic retinopathy, nephropathy, neuropathy, and arterial abnormalities in animal models. Clinical trials in humans are currently in progress.
Similar articles
- Advanced glycation end products: sparking the development of diabetic vascular injury.
Goldin A, Beckman JA, Schmidt AM, Creager MA. Goldin A, et al. Circulation. 2006 Aug 8;114(6):597-605. doi: 10.1161/CIRCULATIONAHA.106.621854. Circulation. 2006. PMID: 16894049 Review. - Advanced glycation end-products and the progress of diabetic vascular complications.
Jakus V, Rietbrock N. Jakus V, et al. Physiol Res. 2004;53(2):131-42. Physiol Res. 2004. PMID: 15046548 Review. - Advanced glycation end products and the kidney.
Bohlender JM, Franke S, Stein G, Wolf G. Bohlender JM, et al. Am J Physiol Renal Physiol. 2005 Oct;289(4):F645-59. doi: 10.1152/ajprenal.00398.2004. Am J Physiol Renal Physiol. 2005. PMID: 16159899 Review. - Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD.
Wu L, Ma L, Nicholson LF, Black PN. Wu L, et al. Respir Med. 2011 Mar;105(3):329-36. doi: 10.1016/j.rmed.2010.11.001. Epub 2010 Nov 26. Respir Med. 2011. PMID: 21112201 - Advanced glycation end products and diabetic foot disease.
Huijberts MS, Schaper NC, Schalkwijk CG. Huijberts MS, et al. Diabetes Metab Res Rev. 2008 May-Jun;24 Suppl 1:S19-24. doi: 10.1002/dmrr.861. Diabetes Metab Res Rev. 2008. PMID: 18442180 Review.
Cited by
- Detoxification of aldehydes by histidine-containing dipeptides: from chemistry to clinical implications.
Xie Z, Baba SP, Sweeney BR, Barski OA. Xie Z, et al. Chem Biol Interact. 2013 Feb 25;202(1-3):288-97. doi: 10.1016/j.cbi.2012.12.017. Epub 2013 Jan 9. Chem Biol Interact. 2013. PMID: 23313711 Free PMC article. - Diabetic wound regeneration using peptide-modified hydrogels to target re-epithelialization.
Xiao Y, Reis LA, Feric N, Knee EJ, Gu J, Cao S, Laschinger C, Londono C, Antolovich J, McGuigan AP, Radisic M. Xiao Y, et al. Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):E5792-E5801. doi: 10.1073/pnas.1612277113. Epub 2016 Sep 19. Proc Natl Acad Sci U S A. 2016. PMID: 27647919 Free PMC article. - Cinnamic acid and its derivatives inhibit fructose-mediated protein glycation.
Adisakwattana S, Sompong W, Meeprom A, Ngamukote S, Yibchok-Anun S. Adisakwattana S, et al. Int J Mol Sci. 2012;13(2):1778-1789. doi: 10.3390/ijms13021778. Epub 2012 Feb 8. Int J Mol Sci. 2012. PMID: 22408423 Free PMC article. - Neuroendocrine-immune aspects of accelerated aging in rheumatoid arthritis.
Härle P, Straub RH. Härle P, et al. Curr Rheumatol Rep. 2005 Oct;7(5):389-94. doi: 10.1007/s11926-005-0027-6. Curr Rheumatol Rep. 2005. PMID: 16174490 Review. - Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.
Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, Imaizumi T. Nakamura K, et al. Mol Med. 2007 Mar-Apr;13(3-4):185-9. doi: 10.2119/2006–00090.Nakamura. Mol Med. 2007. PMID: 17592553 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical